拜耳-话题@MedSci

#拜耳#

119篇内容 | 2992人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1318418, encodeId=b622131841854, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=FDA授予拜耳riociguat 2个孤儿药地位认定, objectType=article, longId=25166, objectId=7e422516695, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7e422516695, replyNumber=0, likeNumber=64, createdTime=2013-10-02, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e422516695, moduleTitle=FDA授予拜耳riociguat 2个孤儿药地位认定, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7e422516695)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318417, encodeId=ca9b131841e70, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳向EMA提交Stivarga治疗GIST新适应症申请, objectType=article, longId=24123, objectId=e08c2412394, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e08c2412394, replyNumber=0, likeNumber=69, createdTime=2013-09-11, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e08c2412394, moduleTitle=拜耳向EMA提交Stivarga治疗GIST新适应症申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e08c2412394)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318416, encodeId=8eb21318416dd, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳Eylea新适应症获欧盟批准, objectType=article, longId=23541, objectId=af4d2354129, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af4d2354129, replyNumber=0, likeNumber=62, createdTime=2013-09-01, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af4d2354129, moduleTitle=拜耳Eylea新适应症获欧盟批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af4d2354129)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318415, encodeId=c9b213184153b, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=FDA授予拜耳多吉美（Nexavar）sNDA优先审查资格, objectType=article, longId=23456, objectId=461f234568d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=461f234568d, replyNumber=0, likeNumber=88, createdTime=2013-08-30, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=461f234568d, moduleTitle=FDA授予拜耳多吉美（Nexavar）sNDA优先审查资格, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=461f234568d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318414, encodeId=f0ab1318414b5, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳Stivarga新适应症获日本批准, objectType=article, longId=23240, objectId=18f9232401a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18f9232401a, replyNumber=0, likeNumber=97, createdTime=2013-08-23, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18f9232401a, moduleTitle=拜耳Stivarga新适应症获日本批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18f9232401a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318412, encodeId=5faa131841260, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点, objectType=article, longId=22742, objectId=237922e4273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=237922e4273, replyNumber=0, likeNumber=78, createdTime=2013-08-09, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=237922e4273, moduleTitle=拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=237922e4273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318413, encodeId=57b7131841395, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=FDA顾问委员会建议批准拜耳肺动脉高压药物riociguat, objectType=article, longId=22744, objectId=047122e447c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=047122e447c, replyNumber=0, likeNumber=60, createdTime=2013-08-09, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=047122e447c, moduleTitle=FDA顾问委员会建议批准拜耳肺动脉高压药物riociguat, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=047122e447c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318411, encodeId=a0a413184110b, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=FDA：拜耳肺动脉高压药物riociguat应予以批准, objectType=article, longId=22662, objectId=ac0d2266215, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ac0d2266215, replyNumber=0, likeNumber=67, createdTime=2013-08-07, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ac0d2266215, moduleTitle=FDA：拜耳肺动脉高压药物riociguat应予以批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ac0d2266215)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318410, encodeId=97401318410f7, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=CHMP建议批准拜耳Eylea用于视网膜中央静脉阻塞(CRVO)继发黄斑水肿（ME）, objectType=article, longId=22426, objectId=41c4224261a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41c4224261a, replyNumber=0, likeNumber=52, createdTime=2013-08-02, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41c4224261a, moduleTitle=CHMP建议批准拜耳Eylea用于视网膜中央静脉阻塞(CRVO)继发黄斑水肿（ME）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41c4224261a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318408, encodeId=f1f3131840805, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳向EMA及FDA提交多吉美治疗甲状腺癌的上市许可申请(MA), objectType=article, longId=20868, objectId=13a720868eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=13a720868eb, replyNumber=0, likeNumber=71, createdTime=2013-07-05, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=13a720868eb, moduleTitle=拜耳向EMA及FDA提交多吉美治疗甲状腺癌的上市许可申请(MA), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=13a720868eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318409, encodeId=d6ff1318409b9, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗, objectType=article, longId=20869, objectId=d9a32086951, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d9a32086951, replyNumber=0, likeNumber=73, createdTime=2013-07-05, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d9a32086951, moduleTitle=CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d9a32086951)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318407, encodeId=4a0e131840e3a, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳和Onyx公布regorafenib胃肠道III期GRID研究积极数据, objectType=article, longId=6977, objectId=192969e72d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=192969e72d, replyNumber=0, likeNumber=73, createdTime=2012-06-11, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=192969e72d, moduleTitle=拜耳和Onyx公布regorafenib胃肠道III期GRID研究积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=192969e72d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318405, encodeId=b3ad1318405a4, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳向EMA及FDA提交抗癌新药regorafenib上市许可申请, objectType=article, longId=6481, objectId=3b6464812c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3b6464812c, replyNumber=0, likeNumber=69, createdTime=2012-05-26, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3b6464812c, moduleTitle=拜耳向EMA及FDA提交抗癌新药regorafenib上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3b6464812c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318406, encodeId=071e13184068d, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=强生拜耳的拜瑞妥（Xarelto）新适应证申请遭FDA评审委员会拒绝, objectType=article, longId=6484, objectId=92836484f5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=92836484f5, replyNumber=0, likeNumber=62, createdTime=2012-05-26, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=92836484f5, moduleTitle=强生拜耳的拜瑞妥（Xarelto）新适应证申请遭FDA评审委员会拒绝, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=92836484f5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318402, encodeId=3bd71318402d1, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳公司抗凝血药物Xarelto获英国NICE推荐, objectType=article, longId=5409, objectId=fe305409c3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fe305409c3, replyNumber=0, likeNumber=53, createdTime=2012-04-18, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fe305409c3, moduleTitle=拜耳公司抗凝血药物Xarelto获英国NICE推荐, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fe305409c3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318403, encodeId=1a8c1318403a6, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳和Onyx公司公布regorafenib肠胃间质瘤III期研究积极数据, objectType=article, longId=5425, objectId=e98d5425fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e98d5425fc, replyNumber=0, likeNumber=70, createdTime=2012-04-18, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e98d5425fc, moduleTitle=拜耳和Onyx公司公布regorafenib肠胃间质瘤III期研究积极数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e98d5425fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318404, encodeId=535d13184048c, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳向欧盟提交拜瑞妥（Xarelto）上市许可申请, objectType=article, longId=5430, objectId=675254302e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=675254302e, replyNumber=0, likeNumber=54, createdTime=2012-04-18, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=675254302e, moduleTitle=拜耳向欧盟提交拜瑞妥（Xarelto）上市许可申请, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=675254302e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318401, encodeId=14b71318401ce, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳制药新药Gadavist通过FDA批准, objectType=article, longId=5264, objectId=0ae45264de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ae45264de, replyNumber=0, likeNumber=96, createdTime=2012-04-16, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ae45264de, moduleTitle=拜耳制药新药Gadavist通过FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ae45264de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1318400, encodeId=f84b13184001d, content=<a href='/topic/show?id=9a535625968' target=_blank style='color:#2F92EE;'>#拜耳#</a>, objectTitle=拜耳胰岛素学院研究基金启动通告, objectType=article, longId=2723, objectId=934f2e2318, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=934f2e2318, replyNumber=0, likeNumber=59, createdTime=2011-06-22, rootId=0, userName=ying_wu, userId=11b4465, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=934f2e2318, moduleTitle=拜耳胰岛素学院研究基金启动通告, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=934f2e2318)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

拜耳

2020-05-29

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

FDA授予拜耳riociguat 2个孤儿药地位认定

2013-10-02

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳向EMA提交Stivarga治疗GIST新适应症申请

2013-09-11

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳Eylea新适应症获欧盟批准

2013-09-01

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

FDA授予拜耳多吉美（Nexavar）sNDA优先审查资格

2013-08-30

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳Stivarga新适应症获日本批准

2013-08-23

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳Eylea 2个III期糖尿病性黄斑水肿试验均达主要终点

2013-08-09

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

FDA顾问委员会建议批准拜耳肺动脉高压药物riociguat

2013-08-09

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

FDA：拜耳肺动脉高压药物riociguat应予以批准

2013-08-07

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

CHMP建议批准拜耳Eylea用于视网膜中央静脉阻塞(CRVO)继发黄斑水肿（ME）

2013-08-02

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳向EMA及FDA提交多吉美治疗甲状腺癌的上市许可申请(MA)

2013-07-05

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

CHMP建议批准拜耳regorafenib用于转移性结直肠癌(mCRC)治疗

2013-07-05

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳和Onyx公布regorafenib胃肠道III期GRID研究积极数据

2012-06-11

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳向EMA及FDA提交抗癌新药regorafenib上市许可申请

2012-05-26

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

强生拜耳的拜瑞妥（Xarelto）新适应证申请遭FDA评审委员会拒绝

2012-05-26

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳公司抗凝血药物Xarelto获英国NICE推荐

2012-04-18

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳和Onyx公司公布regorafenib肠胃间质瘤III期研究积极数据

2012-04-18

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳向欧盟提交拜瑞妥（Xarelto）上市许可申请

2012-04-18

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳制药新药Gadavist通过FDA批准

2012-04-16

ying_wu (审核中...)

前往app查看评论内容

#拜耳#

拜耳胰岛素学院研究基金启动通告

2011-06-22

科室
- - 订阅+
  - 更多科室
工具
服务